|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention
Datamonitor, May 2004, Pages: 238
Only 13-28% of drug-treated type 2 diabetes patients receive insulin therapy. The late initiation of insulin reflects the general trend that it is a last resort therapy in the treatment of type 2 diabetes. We believe that there will be a shift towards earlier initiation of insulin in the future, along with increased uptake, following the introduction of non-injected insulin.
Scope
Analysis of interviews with 388 physicians in the 7 major markets, validated via in-depth interviews with international experts
Determination of the prevalence of type 1 and type 2 diabetes, with forecasts to 2012
Analysis of the use of insulin therapy in the treatment of type 2 diabetes by line of therapy and evaluation of early vs. late initiation of insulin
Assessment of the potential patient population for non-injected insulin: evaluation of switch from injected insulin and add-on to OAD therapy
Highlights
Due to rising rates of obesity and the aging population, type 2 diabetes is an emerging epidemic: We estimate there will be 50.1m diabetics in the seven major markets in 2012. Despite the large patient population, Our physician research reveals that only 50% of type 2 diabetics across the seven major markets are diagnosed.
The late initiation of insulin reflects the trend that insulin is a therapy of last resort in the treatment of type 2 diabetes. Although some experts believe that the earlier initiation of insulin is emerging, additional clinical trials are required to support this strategy.
Non-injected insulins are expected to overcome the key unmet need in the insulin market by providing a more convenient mode of administration, and they are also expected to increase the overall use of insulin in type 2 diabetes patients and shorten the time to initiation.
Reasons to Purchase
Understand the factors limiting the use of insulin in type 2 diabetes, based on both physician and patient perception
Validate product forecasting based on diagnosis and treatment rates, and the estimated future use of insulin in the treatment of type 2 diabetes
Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products
Customers who bought this item also bought
Metabolic Syndrome: New Opportunities in Diagnostics and Therapeutics
The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets
Commercial Perspectives: Diabetes - Type 2 Epidemic Driving Aggressive Therapy
Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity
Diabetes for Dummies, UK Edition
The Impact of Islet Cell Transplantation on the Type 1 Diabetes Market September 29, 2005
The Metabolic Syndrome
|
|
|
|
